Denali Therapeutics (4DN) Price & Analysis

Compare

7 Followers

4DN Stock Chart & Stats

€17.31

€2.53(14.09%)

At close: Jan 08 4:00 PM EST

€17.31

€2.53(14.09%)

Day’s Range― - ―

52-Week Range€10.17 - €21.14

Previous CloseN/A

Volume0.00

Average Volume (3M)101.00

Market Cap

€2.76B

Enterprise Value€3.21B

Total Cash (Recent Filing)€848.20M

Total Debt (Recent Filing)€44.40M

Price to Earnings (P/E)―

Beta0.88

Next Earnings

Mar 02, 2026

EPS Estimate

-0.62

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.62

Shares Outstanding156,158,370

10 Day Avg. Volume31

30 Day Avg. Volume101

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)2.73

Price to Sales (P/S)0.00

P/FCF Ratio-9.22

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€27.53

Price Target Upside59.03% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Biomarker Validation And Regulatory PathwayRobust reductions and normalization of cerebrospinal fluid heparan sulfate for DNL126, together with alignment with the FDA on using a CSF biomarker as a surrogate endpoint, support a streamlined path to accelerated approval for Sanfilippo syndrome where no approved therapies exist.

Blood–brain Barrier Delivery PlatformThe proprietary Enzyme Transport Vehicle that enables delivery across the blood–brain barrier to neurons, peripheral nerves, and muscle fibers enhances the likelihood of meaningful central nervous system and systemic benefit and reduces development and commercial execution risk.

Commercial Funding And Launch ReadinessThe Royalty Pharma financing deal and internal manufacturing capacity strengthen the balance sheet and operational independence, positioning the company to execute a well-capitalized commercialization of tividenofusp alfa and follow‑on products.

Bears Say

Patient Treatment Burden And Safety ProfileSwitching patients from current home‑based therapies to tividenofusp alfa could require extended hospital‑based infusions and the therapy carries infusion‑related reactions as the most common adverse event, which could limit patient uptake and complicate commercial adoption.

Preclinical Safety And Clinical Hold RiskAn FDA clinical hold and requests for amended dosing and enhanced safety monitoring for the Pompe program after preclinical hypersensitivity signals raise the risk of delayed development and additional trial requirements.

Regulatory Scrutiny On Single‑arm TrialsHeightened FDA caution about approving therapies based on single-arm studies and surrogate endpoints increases approval uncertainty for programs that rely on open‑label data rather than randomized controls.

Denali Therapeutics News

Denali Therapeutics: Strengthening LSD Clinical Profile and Attractive Risk‑Reward Support Buy Rating

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Denali Therapeutics. The associated...

4d ago

DNLI

Denali Therapeutics Advances New Early-Stage Alzheimer’s Drug Into Phase 1b Testing

Denali Therapeutics ($DNLI) announced an update on their ongoing clinical study. Study Overview Denali Therapeutics is launching a...

27d ago

DNLI

Denali Therapeutics price target raised to $40 from $32 at Morgan Stanley

Morgan Stanley analyst Sean Laaman raised the firm’s price target on Denali Therapeutics (DNLI) to $40 from $32...

1M ago

DNLI

Denali Therapeutics assumed with a Buy at UBS

UBS assumed coverage of Denali Therapeutics (DNLI) with a Buy rating and a price target of $25, up...

1M ago

DNLI

Denali Therapeutics Sets 2026 Priorities Ahead of Tividenofusp Decision

Denali Therapeutics ( ($DNLI) ) has provided an update. On January 6, 2026, Denali Therapeutics outlined its key...

1M ago

DNLI

Denali Therapeutics announces key milestones, priorities for 2026

Denali Therapeutics (DNLI) announced key anticipated milestones and priorities for 2026 across its portfolio of investigational therapies for...

1M ago

DNLI

Denali Therapeutics announces publication of Phase 1/2 study of DNL310

Denali Therapeutics (DNLI) announced the publication of results from the open-label Phase 1/2 clinical trial of its investigational,...

1M ago

DNLI

Denali Therapeutics price target lowered to $30 from $31 at Wedbush

Wedbush analyst Laura Chico lowered the firm’s price target on Denali Therapeutics (DNLI) to $30 from $31 and...

2M ago

DNLI

Denali Therapeutics Announces $200M Public Offering

Denali Therapeutics ( ($DNLI) ) has shared an update. On December 9, 2025, Denali Therapeutics entered into an...

2M ago

DNLI

Denali Therapeutics 9.143M share Spot Secondary priced at $17.50

The deal range was $17.00-$18.00. Goldman Sachs, JPMorgan, Morgan Stanley and Jefferies acted as joint book running managers...

2M ago

DNLI

Closing Bell Movers: GE Vernova up 6% on raised outlook, doubled dividend

In the opening hour of the evening session, U.S. equity futures are marginally lower, with S&P e-minis slipping...

2M ago

GEV

GME

Denali Therapeutics TBA Spot Secondary; price range $17.00-$18.00

Goldman Sachs, JPMorgan, Morgan Stanley and Jefferies are acting as joint book running managers for the offering. Published...

2M ago

DNLI

Denali Therapeutics offers to sell $200M in common stock

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Jefferies LLC are...

2M ago

DNLI

Denali Therapeutics price target raised to $29 from $26 at BofA

BofA raised the firm’s price target on Denali Therapeutics (DNLI) to $29 from $26 and keeps a Buy...

2M ago

DNLI

4DN FAQ

What was Denali Therapeutics’s price range in the past 12 months?

Denali Therapeutics lowest stock price was €10.17 and its highest was €21.14 in the past 12 months.

What is Denali Therapeutics’s market cap?

Denali Therapeutics’s market cap is €2.76B.

When is Denali Therapeutics’s upcoming earnings report date?

Denali Therapeutics’s upcoming earnings report date is Mar 02, 2026 which is in 20 days.

How were Denali Therapeutics’s earnings last quarter?

Denali Therapeutics released its earnings results on Nov 06, 2025. The company reported -€0.621 earnings per share for the quarter, beating the consensus estimate of -€0.628 by €0.007.

Is Denali Therapeutics overvalued?

According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Denali Therapeutics pay dividends?

Denali Therapeutics does not currently pay dividends.

What is Denali Therapeutics’s EPS estimate?

Denali Therapeutics’s EPS estimate is -0.62.

How many shares outstanding does Denali Therapeutics have?

Denali Therapeutics has 156,158,370 shares outstanding.

What happened to Denali Therapeutics’s price movement after its last earnings report?

Denali Therapeutics reported an EPS of -€0.621 in its last earnings report, beating expectations of -€0.628. Following the earnings report the stock price went down -3.158%.

Which hedge fund is a major shareholder of Denali Therapeutics?

Currently, no hedge funds are holding shares in DE:4DN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Denali Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-44.44%

Trailing 12-Months

Asset Growth

-27.40%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Denali Therapeutics

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Denali Therapeutics (4DN) Earnings & Revenues

Historic Earnings Reports

4DN Stock 12 Month Forecast

Average Price Target

€27.53

▲(59.03% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"€10","16":"€16","22":"€22","28":"€28","34":"€34"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33.593628,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€33.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.528111833333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€27.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.9960175,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,16,22,28,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.01,19.208740615384617,20.407481230769232,21.606221846153847,22.804962461538462,24.003703076923077,25.202443692307696,26.40118430769231,27.599924923076927,28.79866553846154,29.997406153846157,31.196146769230772,32.39488738461539,{"y":33.593628,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.01,18.74216244871795,19.4743248974359,20.206487346153846,20.938649794871797,21.670812243589744,22.402974692307694,23.13513714102564,23.867299589743592,24.59946203846154,25.33162448717949,26.063786935897436,26.795949384615383,{"y":27.528111833333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.01,18.239693653846157,18.46938730769231,18.699080961538463,18.928774615384615,19.15846826923077,19.388161923076925,19.617855576923077,19.847549230769232,20.077242884615387,20.30693653846154,20.536630192307694,20.766323846153846,{"y":20.9960175,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.39,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.515,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.945,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.23,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.115,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.16,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.01,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >